Pantherics Incorporated received a $224,756 Phase I Small Business Technology Transfer (STTR) grant from the National Institutes of Health (NIH) to advance research on a fundamentally novel asthma control drug. The first-in-class drug, MIDD0301, was discovered by researchers at the Milwaukee Institute for Drug Discovery at the University of Wisconsin-Milwaukee (WI) and Columbia University (NY). Funding from this STTR grant will be used to advance MIDD0301 to IND enabling pre-clinical studies.

Milwaukee, WI, May 7, 20, 2019